AR075179A1 - Formulaciones galenicas de compuestos organicos que comprenden alisquireno - Google Patents
Formulaciones galenicas de compuestos organicos que comprenden alisquirenoInfo
- Publication number
- AR075179A1 AR075179A1 ARP100100193A ARP100100193A AR075179A1 AR 075179 A1 AR075179 A1 AR 075179A1 AR P100100193 A ARP100100193 A AR P100100193A AR P100100193 A ARP100100193 A AR P100100193A AR 075179 A1 AR075179 A1 AR 075179A1
- Authority
- AR
- Argentina
- Prior art keywords
- dosage form
- alisquirene
- tablet
- heart failure
- outer coating
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 150000002894 organic compounds Chemical class 0.000 title 1
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 239000006186 oral dosage form Substances 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 abstract 1
- 208000021642 Muscular disease Diseases 0.000 abstract 1
- 201000009623 Myopathy Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 239000007888 film coating Substances 0.000 abstract 1
- 238000009501 film coating Methods 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 230000000873 masking effect Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007892 solid unit dosage form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una forma de dosificacion unitaria solida para su administracion oral en la forma de una tableta que tiene un nucleo y un recubrimiento externo, en donde: el nucleo de la tableta comprende una cantidad terapéuticamente efectiva de Alisquireno, o de una sal farmacéuticamente aceptable del mismo, y el recubrimiento externo está en la forma de un recubrimiento de película, el cual tiene propiedades enmascaradoras de sabor y/o una funcionalidad de liberacion controlada. De preferencia, el nucleo tableta es parte de un sistema de multiples partículas, en particular una minitableta. La forma de dosificacion oral solida es en particular adecuada para uso pediátrico. Reivindicacion 13: Una forma de dosificacion oral solida de acuerdo con la reivindicacion 9, para utilizarse en el tratamiento de hipertension, insuficiencia cardiaca congestiva, angina, infarto de miocardio, ateroesclerosis, nefropatía diabética, miopatía cardíaca diabética, insuficiencia renal, enfermedad vascular periférica, hipertrofia de ventrículo izquierdo, disfuncion cognitiva, embolia, dolor de cabeza, e insuficiencia cardiaca cronica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09151496 | 2009-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075179A1 true AR075179A1 (es) | 2011-03-16 |
Family
ID=40770648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100193A AR075179A1 (es) | 2009-01-28 | 2010-01-27 | Formulaciones galenicas de compuestos organicos que comprenden alisquireno |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20110287100A1 (es) |
| EP (1) | EP2391345B1 (es) |
| JP (1) | JP2012516299A (es) |
| KR (1) | KR20110117199A (es) |
| CN (1) | CN102300558A (es) |
| AR (1) | AR075179A1 (es) |
| AU (1) | AU2010209787B2 (es) |
| BR (1) | BRPI1007452A2 (es) |
| CA (1) | CA2749531A1 (es) |
| CL (1) | CL2011001817A1 (es) |
| CO (1) | CO6400184A2 (es) |
| EC (1) | ECSP11011289A (es) |
| ES (1) | ES2525648T3 (es) |
| IL (1) | IL213918A0 (es) |
| MA (1) | MA33060B1 (es) |
| MX (1) | MX2011007779A (es) |
| MY (1) | MY153852A (es) |
| NZ (1) | NZ593622A (es) |
| PE (1) | PE20110943A1 (es) |
| PL (1) | PL2391345T3 (es) |
| PT (1) | PT2391345E (es) |
| RU (1) | RU2535090C2 (es) |
| SG (1) | SG172226A1 (es) |
| TN (1) | TN2011000307A1 (es) |
| TW (1) | TWI468191B (es) |
| WO (1) | WO2010086312A1 (es) |
| ZA (1) | ZA201104489B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5822758B2 (ja) * | 2011-03-02 | 2015-11-24 | 第一三共ヘルスケア株式会社 | 速溶性防湿フィルムコーティング製剤及びその製造方法 |
| EP2596802A1 (en) * | 2011-11-23 | 2013-05-29 | PLS-Design GmbH | Pharmaceutical composition for treatment of allergic reactions |
| CA3010778C (en) | 2016-02-03 | 2024-02-27 | Novartis Ag | Galenic formulations of organic compounds |
| JP7461295B2 (ja) * | 2018-08-10 | 2024-04-03 | キッセイ薬品工業株式会社 | スクロオキシ水酸化鉄含有顆粒及び医薬組成物 |
| US11185508B2 (en) * | 2019-02-22 | 2021-11-30 | Catalent U.K. Swindon Zydis Limited | Preserving functionally-coated API particles produced by solventless mixing processes in aqueous suspension |
| AR118419A1 (es) | 2019-02-22 | 2021-10-06 | Catalent Uk Swindon Zydis Ltd | Minimización de aglomeración de material de revestimiento de partícula de medicamento durante el almacenaje para estabilizar los tiempos de desintegración de productos farmacéuticos |
| BR112021016408A2 (pt) | 2019-02-22 | 2021-10-13 | Catalent U.K. Swindon Zydis Limited | Minimização de aeração de suspensões durante mistura em linha |
| HUE064472T2 (hu) | 2019-02-22 | 2024-03-28 | Catalent Uk Swindon Zydis Ltd | Agglomeráció, aeráció minimalizálása, és ibuprofent tartalmazó gyógyszerészeti készítmények bevonatának védelme |
| WO2021011538A1 (en) * | 2019-07-15 | 2021-01-21 | R.P. Scherer Technologies, Llc | Capsule dosage forms, methods of preparation and methods of use thereof |
| CN115968281A (zh) | 2020-07-31 | 2023-04-14 | 康特伦英国斯温顿捷迪斯有限公司 | 包含经包衣api的药物组合物 |
| AU2021391823A1 (en) | 2020-12-03 | 2023-06-29 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| CA3216359A1 (en) | 2021-04-07 | 2022-10-13 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025105451A1 (ja) * | 2023-11-17 | 2025-05-22 | 第一三共ヘルスケア株式会社 | 固形製剤 |
| US12441996B2 (en) | 2023-12-08 | 2025-10-14 | Battelle Memorial Institute | Use of DNA origami nanostructures for molecular information based data storage systems |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| DE19842753A1 (de) * | 1998-09-18 | 2000-03-23 | Bayer Ag | Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| AR034813A1 (es) * | 2001-07-20 | 2004-03-17 | Novartis Ag | Composiciones farmaceuticas y uso de las mismas |
| WO2004100871A2 (en) * | 2003-05-09 | 2004-11-25 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and a renin inhibitor |
| AR048431A1 (es) * | 2004-03-17 | 2006-04-26 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| WO2005105054A1 (en) * | 2004-04-15 | 2005-11-10 | Dr. Reddy's Laboratories Ltd. | Dosage form having polymorphic stability |
| MX2007004020A (es) * | 2004-10-08 | 2007-05-24 | Novartis Ag | Uso de inhibidores de renina para la prevencion o tratamiento de disfuncion diastolica o falla cardiaca diastolica. |
| BRPI0817275A2 (pt) * | 2007-09-28 | 2015-06-16 | Novartis Ag | Combinação farmacêutica de alisquireno e valsartana |
-
2010
- 2010-01-27 RU RU2011135417/15A patent/RU2535090C2/ru not_active IP Right Cessation
- 2010-01-27 PT PT107020927T patent/PT2391345E/pt unknown
- 2010-01-27 PE PE2011001391A patent/PE20110943A1/es not_active Application Discontinuation
- 2010-01-27 BR BRPI1007452A patent/BRPI1007452A2/pt not_active IP Right Cessation
- 2010-01-27 MA MA34114A patent/MA33060B1/fr unknown
- 2010-01-27 JP JP2011546822A patent/JP2012516299A/ja active Pending
- 2010-01-27 CN CN2010800057033A patent/CN102300558A/zh active Pending
- 2010-01-27 AU AU2010209787A patent/AU2010209787B2/en not_active Ceased
- 2010-01-27 AR ARP100100193A patent/AR075179A1/es unknown
- 2010-01-27 US US13/145,454 patent/US20110287100A1/en not_active Abandoned
- 2010-01-27 KR KR1020117019809A patent/KR20110117199A/ko not_active Ceased
- 2010-01-27 PL PL10702092T patent/PL2391345T3/pl unknown
- 2010-01-27 CA CA2749531A patent/CA2749531A1/en not_active Abandoned
- 2010-01-27 TW TW99102290A patent/TWI468191B/zh not_active IP Right Cessation
- 2010-01-27 MX MX2011007779A patent/MX2011007779A/es not_active Application Discontinuation
- 2010-01-27 ES ES10702092.7T patent/ES2525648T3/es active Active
- 2010-01-27 MY MYPI2011003186A patent/MY153852A/en unknown
- 2010-01-27 EP EP10702092.7A patent/EP2391345B1/en not_active Not-in-force
- 2010-01-27 WO PCT/EP2010/050886 patent/WO2010086312A1/en not_active Ceased
- 2010-01-27 SG SG2011044450A patent/SG172226A1/en unknown
- 2010-01-27 NZ NZ593622A patent/NZ593622A/en not_active IP Right Cessation
-
2011
- 2011-06-16 TN TN2011000307A patent/TN2011000307A1/fr unknown
- 2011-06-17 ZA ZA2011/04489A patent/ZA201104489B/en unknown
- 2011-07-04 IL IL213918A patent/IL213918A0/en unknown
- 2011-07-27 CL CL2011001817A patent/CL2011001817A1/es unknown
- 2011-07-28 CO CO11095153A patent/CO6400184A2/es not_active Application Discontinuation
- 2011-08-26 EC EC2011011289A patent/ECSP11011289A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011007779A (es) | 2011-08-12 |
| PT2391345E (pt) | 2014-12-03 |
| ZA201104489B (en) | 2012-02-29 |
| ECSP11011289A (es) | 2011-09-30 |
| CL2011001817A1 (es) | 2012-01-13 |
| AU2010209787A1 (en) | 2011-07-14 |
| WO2010086312A1 (en) | 2010-08-05 |
| PE20110943A1 (es) | 2012-01-22 |
| US20110287100A1 (en) | 2011-11-24 |
| TW201038300A (en) | 2010-11-01 |
| ES2525648T3 (es) | 2014-12-26 |
| KR20110117199A (ko) | 2011-10-26 |
| SG172226A1 (en) | 2011-07-28 |
| CO6400184A2 (es) | 2012-03-15 |
| MA33060B1 (fr) | 2012-02-01 |
| RU2011135417A (ru) | 2013-03-10 |
| TN2011000307A1 (en) | 2012-12-17 |
| AU2010209787B2 (en) | 2013-06-06 |
| MY153852A (en) | 2015-03-31 |
| TWI468191B (zh) | 2015-01-11 |
| NZ593622A (en) | 2013-12-20 |
| EP2391345B1 (en) | 2014-09-03 |
| PL2391345T3 (pl) | 2015-03-31 |
| CN102300558A (zh) | 2011-12-28 |
| HK1161125A1 (en) | 2012-08-24 |
| JP2012516299A (ja) | 2012-07-19 |
| IL213918A0 (en) | 2011-07-31 |
| EP2391345A1 (en) | 2011-12-07 |
| RU2535090C2 (ru) | 2014-12-10 |
| CA2749531A1 (en) | 2010-08-05 |
| BRPI1007452A2 (pt) | 2016-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075179A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno | |
| AR066168A1 (es) | Formulaciones galenicas de compuestos organicos | |
| AR079552A1 (es) | Metodo para el tratamiento de la fibrilacion atrial. formulacion farmaceutica | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| JP2016053040A5 (es) | ||
| EP4342540A3 (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| CL2007001870A1 (es) | Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d | |
| DOP2006000170A (es) | Nuevos derivados de espirocromanona | |
| JP2013136617A5 (es) | ||
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| AR048588A1 (es) | Uso de inhibidores de la fosfodiesterasa de tipo iii (pde iii) para la reduccion del tamano del corazon en mamiferos que padecen insuficiencia cardiaca | |
| GT201200164A (es) | "nuevos compuestos de espiropiperidina" | |
| EA201100358A1 (ru) | Дабигатран для чрескожной хирургической катетеризации сердца | |
| JP2016511753A5 (es) | ||
| MX368157B (es) | Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico. | |
| EA201291247A1 (ru) | ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ В ФОРМЕ ДВУХСЛОЙНЫХ ТАБЛЕТОК, СОДЕРЖАЩИХ ИНГИБИТОР HMG-CoA РЕДУКТАЗЫ И ИРБЕСАРТАН | |
| CO6382133A2 (es) | Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional | |
| CL2013000513A1 (es) | Uso de una composicion farmaceutica que comprende: a) un compuesto monohidratado formado por dos aniones y un cation o b) valsartan y un etil-ester de acido, para el tratamiento de hipertension y/o la prevencion o el tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante. | |
| JP2013166781A5 (es) | ||
| ECSP16005195A (es) | Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán | |
| RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза | |
| HRP20201187T1 (hr) | Derivat triazolopirazinona koristan kao inhibitor ljudskog pde1 | |
| EA201590474A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ | |
| AR075988A1 (es) | Compuesto de piridiloxi - pirrolidina inhibidor de recaptacion de serotonina y norepinefrina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de dolor cronico | |
| AR073384A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno y amlodipina, y metodo de preparacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |